# Evaluation of the Pharmacokinetics/Pharmacodynamics and Safety/Tolerability of IN-C005 and IN-A001 in Healthy Caucasians

> **NCT05005065** · PHASE1 · COMPLETED · sponsor: **HK inno.N Corporation** · enrollment: 20 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** IN-C005 X mg
- **DRUG:** IN-A001 Y mg
- **DRUG:** IN-C005 Y mg
- **DRUG:** IN-C005 Z mg

## Key facts

- **NCT ID:** NCT05005065
- **Lead sponsor:** HK inno.N Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-06
- **Primary completion:** 2021-11-18
- **Final completion:** 2021-11-30
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2022-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05005065

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05005065, "Evaluation of the Pharmacokinetics/Pharmacodynamics and Safety/Tolerability of IN-C005 and IN-A001 in Healthy Caucasians". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05005065. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*